Introduction
Schistosomiasis is a water-borne human parasitic infection prevalent in Asia, Africa, Middle East and South America infecting more than 200 million people. 1 Infection occurs when larval stages of the parasite (Schistosomula) enter through intact skin. Schistosomula stay in the skin for more than 3 days migrating through various layers of the epidermis and dermis. Despite tissue damage due to migrating parasites, very little inflammatory responses were seen in the skin. [2] [3] [4] Previous studies from our laboratory showed that this subdued inflammatory response was due to a 16-kDa protein (designated Sm16) present abundantly in the secretions of schistosomula. 5 In vitro studies demonstrated that Sm16 stimulates IL-1ra production in human keratinocytes and suppresses transcription of the proinflammatory cytokines IL-1␣ and IL-1␤. 6 Further studies showed that Sm16 inhibits antigen-induced lymphoproliferation and suppress IL-2 production from spleen and skin-draining lymph node cells. 5 When injected intradermally along with a pro-inflammatory stimulus, such as bacterial lipopolysaccharide (LPS), Sm16 inhibited ICAM-1 expression and neutrophil infiltration into the skin tissue. 7 Thus, Sm16 showed properties of an antiinflammatory agent. Subsequently, the gene encoding for Sm16 was cloned and recombinant Sm16 was expressed. 8 Intradermal gene delivery or transfer of naked DNA is an exciting new approach that has generated consider- able interest because of its unique ability to introduce any genes of interest into the skin tissue and express the gene product. Several functional genes have been expressed in the skin for therapeutic application using this simple but elegant technique. [9] [10] [11] For example, injection of IL-8 encoding plasmid into the skin induced neutrophil recruitment. 12 Similarly, IL-6 and IL-10 gene expression was demonstrated in the skin following gene transfer. 13, 14 Application of a 8 aa peptide sequence corresponding to the transmembrane region of T cell receptor alpha chain or DNA encoding the above peptide on to the surface of the skin resulted in local immunosuppression. 15 Based on these reports and given the fact that Sm16 has potential anti-inflammatory functions in vitro and in vivo, 6, 7 we wanted to evaluate whether gene coding for Sm16 could be used similarly to alleviate an inflammatory response in the skin.
Results

Expression of Sm16 gene in mice skin
Using GFP (green fluorescent protein) as a reporter protein, the expression of recombinant Sm16:GFP protein was first confirmed in a eukaryotic system by transfecting the gene construct into NIH-3T3 fibroblast cell line in vitro and monitoring fluorescence under a fluorescence microscope (data not shown). This construct was then used for intradermal delivery. Following intradermal injection of Sm16:GFP construct, fluorescence was seen mostly in the basal epidermal cells, dermal cells and in cells associated with hair follicles (Figure 1 ). Sm16 gene expression in the skin was further confirmed by RT-PCR analysis using Sm16 gene specific primers (Figure 2a ). Time course analysis after a single intradermal delivery of Sm16:GFP gene showed that the number of transcripts and protein expression decreased gradually with time. By day 7, gene expression levels were very low ( Figure 2c ) and by day 12 no fluorescence could be seen at the site of injection in the skin (data not shown). Skin samples collected from mice injected with control plasmid were negative ( Figure 2 ).
Effect of Sm16 gene delivery on LPS-induced pathology in the skin
Approximately 5 g of LPS was injected into the skin as an inflammatory stimulus. At 36 h after injection of LPS Gene Therapy plus vector DNA, there was severe erythema, increased vascularity and edema on the dermal side of the skin site. However, in mice that received Sm16 gene along with the LPS, there was a marked reduction in erythema and edema (data not shown).
Modulation of LPS-induced inflammatory cytokine gene expression in the skin by Sm16 gene delivery
Pattern of pro-inflammatory cytokine gene expression in the skin after LPS stimulation and subsequent injection of either vector or Sm16 gene was studied by semi-quantitative RT-PCR and macro gene array. Initial RT-PCR studies showed that expression of the pro-inflammatory cytokines IL-1␤ and TNF-␣ were markedly increased in the skin of mice after injection with LPS plus blank vector control (Figure 3a) . However, delivery of Sm16 gene into the skin site of LPS injection showed that by 36 h there was a 2.5-fold reduction in IL-1␤ transcript and four-fold reduction in TNF-␣ transcripts (Figure 3b ). Subsequent analysis of gene expression by macro gene array at 48 h showed significant reduction in the proinflammatory cytokines IL-1␤, TNF-␣, IL-17 and chemokines, MIP-1␣ and MIP-2␣ (Table 1) . RT-PCR analysis showed that by 72 h IL-1␤ transcript was barely seen in the skin of mice that received Sm16 DNA (Figure 3b ).
Effect of intradermal Sm16 gene delivery on LPSinduced neutrophil infiltration into the skin
Injection of LPS into the skin resulted in a massive infiltration of neutrophils and edema at the injection site within 24 h. However, injection of CMV:Sm16 DNA into the same skin site 48 h before LPS injection markedly reduced the neutrophil infiltration ( Figure 4b) . A similar injection of control vector into the same site had no influence on the LPS-induced neutrophil infiltration or edema ( Figure 4a ). Although not as dramatic, a reduction in neutrophil infiltration was also observed when Sm16 DNA was injected 24 h before, along with LPS, 24 h after a Signal intensity of each spot was scanned using an NIH image software. After subtracting the background, the signal values for each sample were normalized to the intensity of G3PDH transcripts. Results are expressed as fold decrease of gene expression compared with vector controls. Data presented are from two similar experiments (Exp 1 and Exp 2) using seven animals per group.
or 48 h after the LPS injection (data not shown). The effect of Sm16 on neutrophil infiltration was more apparent 72 h after Sm16 DNA delivery into the skin whether given before or after LPS injection.
Effect of intradermal Sm16 gene delivery on ICAM-1 expression in the skin
Following LPS-induced cutaneous inflammation, ICAM-1 is expressed on many dermal and epidermal cells potentially allowing extravasation of neutrophils into the skin. 16 Prior injection of control vector into the skin site had no influence on the LPS-induced ICAM-1 expression (Figure 4c ), whereas injection of CMV:Sm16 DNA into the same skin site 48 h before LPS injection markedly reduced the ICAM-1 expression in the skin injection site (Figure 4d ). Similar to neutrophil infiltration, the expression of ICAM-1 also showed a decrease when Sm16 DNA was injected 24 h before, along with LPS, 24 h after or 48 h after the LPS injection (data not shown). This down-regulating effect was more apparent 72 h after Sm16 DNA delivery into the skin. Similar results were obtained when 20 g of excretory secretory products of the S. mansoni parasite containing native Sm16 protein was injected intradermally along with 5 g of LPS (data not shown).
Expression of Sm16 gene in migratory cells and in skin draining lymph nodes
RT-PCR analysis showed the presence of Sm16 transcripts in cells that migrated out of ear explants that were injected with recombinant construct (Figure 2b ). Flow cytometric analysis on the phenotype of cells that migrated out of the skin explants in cultures showed that 50.5 + 3.2% of cells that emigrated out of the skin were positive for DEC205 (Figure 2d ). When these emigrating cells were observed under fluorescence microscope, the DEC205 + cells were also positive for tagged GFP. Quantitative analysis under a fluorescence microscope showed that 51 + 1.5% of cells that migrated from ear explants at 48 h after culture were positive for GFP fluorescence (Figure 1d ). Subsequently, we examined the regional lymph nodes and observed GFP-tagged Sm16 expression in the paracortical areas of the skin draining lymph nodes 48 h after intradermal Sm16 DNA delivery (Figure 1e ). However, fluorescence signal was barely visible by day 7 (data not shown).
Effect of Sm16 gene delivery on regional lymph node cell proliferative response
Sm16 when added to lymph node cells can suppress proliferation of lymphocytes. 6 Since we observed Sm16 tran- trol. These studies showed that ConA-induced lymphoproliferation was substantially reduced in mice that received CMV:Sm16 compared with CMV controls ( Figure 5 ). Time course of study revealed that this inhibitory effect reached maximum levels after 72 h of Sm16 gene delivery and showed a downward trend by day 7 ( Figure 5 ). RT-PCR analysis of corresponding skin samples showed that the expression of gene also decreased gradually by day 7 (Figure 2c ).
Figure 4 LPS-induced neutrophil infiltration and ICAM-1 expression was suppressed after an intradermal injection of Sm16 cDNA. Severe neutrophil infiltration and edema are seen in the skin of mice injected with control vector plus LPS (a), whereas, neutrophil infiltration is minimum in skin sites injected with CMV:Sm16, 48 h before LPS injection (b). Similarly, extensive ICAM-1 expression was present in the dermis, mostly around dermal vessels of mice treated with LPS and control vector (c
Antibody responses after Sm16 gene delivery
We analyzed the sera of mice for antibodies to Sm16 after multiple intradermal injections with CMV:Sm16 recombinant construct. These studies showed no detectable levels of antibodies in the serum for up to 8 weeks after the intradermal gene delivery.
Discussion
Results of these studies suggest that gene therapy using Sm16 plasmid DNA could be potentially used to suppress cellular infiltration in the skin following an inflammatory stimulus. It is well established that exogenous DNA could be expressed in the skin after intradermal delivery of naked DNA. 14, 17, 18 Using a similar approach we expressed the DNA of Sm16, an anti-inflammatory protein produced by the human parasite S. mansoni, in the skin of mice and demonstrate that this gene expression can modulate cutaneous inflammation in vivo. After a single intradermal delivery of Sm16 gene, protein expression was observed in various layers of the skin seemingly within most actively dividing or differentiating cells in the epidermis and dermis. This distribution of gene expression in the skin after intradermal delivery is similar to those reported previously by other groups using several other different genes. 19, 20 Sm16 is a secretory protein released abundantly by the larval stages of S. mansoni. 5 The open reading frame of Sm16 gene consists of 354 bp encoding a protein with 117 aa residues. An 18 aa sequence at the N-terminus constitute a signal peptide that facilitates secretion of the protein by the parasite. 8, 21 Although our Sm16 construct contained the N-terminal leader sequences, we believe that the secretion of Sm16 in the skin is mediated by preprotrypsin leader sequence in the FLAG-CMV vector. This assumption is based on the fact that the GFP construct, which also contains the Sm16 leader sequences, is not secreted. Possibly the Sm16 leader is not recognized by mammalian cells. Thus, following intradermal gene delivery, Sm16 protein is locally produced and secreted into the immediate microenvironment, where it may act in an autocrine, juxtacrine or paracrine fashion regulating the LPS-induced cutaneous inflammation similar to what may be happening around the parasite during their 3-day journey through the skin. 22 Although the mechanism of Sm16-induced anti-inflammatory activity is not fully understood, previously we showed that intradermal injection of Sm16 protein could suppress LPS-induced neutrophil infiltration and down-regulate expression of ICAM-1. 6 Since Sm16 gene could be expressed in the skin following intradermal delivery, in the present study we wanted to evaluate whether Sm16 gene expression would downregulate an inflammatory response in the skin. LPS was used as a pro-inflammatory stimulus in our studies to induce cutaneous inflammation. Results from these studies clearly show that injection of Sm16 gene into an LPSinduced inflammatory site relegate both cellular and molecular changes associated with inflammation. These include suppression of pro-inflammatory cytokine/ chemokine gene expression for IL-1␤, IL-17, MIP-1␣, MIP-2␣ and TNF-␣ in the skin, inhibition of neutrophil infiltration and down-regulation of ICAM-1 that facilitates migration of inflammatory cells into the inflammatory site. All these changes suggest a reversal of LPSinduced inflammation by Sm16 gene delivery. This antiinflammatory effect was evident in the skin for up to 7 days after the gene delivery and correlated with the Sm16 gene expression in the tissue. As the gene expression decreased so did the anti-inflammatory effect (data not shown).
For continued anti-inflammatory effect, there is a need to inject the gene multiple times, which could potentially generate antibodies and neutralize the activity. Therefore, we monitored the levels of circulating antibodies after multiple injections with Sm16 plasmid. These studies showed that intradermal delivery of Sm16 gene failed to induce circulating antibodies in mice. This was not surprising, as previous attempts to immunize mice with Sm16 protein were not successful (K Ramaswamy et al, unpublished). Furthermore, indirect evidence from other studies suggests that mice infected or vaccinated against S. mansoni do not show antibodies against Sm16 protein. 23 Generally, parasites are known to produce several proteins that are less immunogenic in their natural or permissive hosts. 24 This lack of immunogenicity coupled with a blocking effect on neutrophil trafficking and proinflammatory cytokine production promises the potential of Sm16 gene delivery as a useful therapeutic tool for symptomatic alleviation of cellular response in cutaneous inflammation.
Intradermal administration of plasmid DNA results in the uptake of foreign DNA by a variety of cells in the skin such as keratinocytes, fibroblasts and dendritic cells. 25 Expression of the protein in keratinocytes could serve as a local reservoir for targeted effect in the microenvironment. 26 However, as keratinocytes mature and slough off due to normal growth and differentiation of the skin, genes expressed in keratinocytes are lost. 25 Skin fibroblast may express the gene for a longer length of time. 25 However, expression of genes in dendritic cells of the skin (Langerhans cells and dermal dendritic cells) has attracted considerable attention. 27, 28 One of the characteristic features of the dendritic cells is that when activated, these cells will differentiate and migrate to the regional lymph nodes carrying the genes with them. 29 La Cava et al 30 showed that after intradermal immunization, naked DNA is transported from the site of injection to lymph node and spleen. Under in vitro conditions, these migratory cells could be collected using a skin organ culture system. 31 Using a similar set up, we show that Sm16 gene is expressed following intradermal delivery in dendritic cells emigrating from skin explants in culture. Although we did not see any Sm16 transcript in the lymph nodes, we did observe low levels of reporter gene expression in the paracortical area of the lymph nodes (Figure 1e ). Previously we reported that Sm16 protein could suppress lymphoproliferation in vitro. 5 This might explain the failure of lymph node cells to respond to ConA after Sm16 gene transfer. The inhibitory effect on lymphoproliferation correlated with Sm16 gene expression in the skin. As the level of gene expression decreased in the skin tissue, so did the inhibitory effect.
In conclusion, our studies show that intradermal delivery of a gene coding for a protein with anti-inflammatory property is a promising approach for ameliorating inflammatory responses in the skin.
Materials and methods
Construction of recombinant plasmids
Green fluorescent protein (GFP) reporter construct:
The open reading frame (ORF) of Sm16 gene (coding for 117 aa) cloned as a fusion to the N-terminus of enhanced GPF (EGFP) in EGFP-N3 vector (Clontech, Palo Alto, CA, USA) was used as a reporter protein for monitoring the expression of Sm16 in cells and tissues. Briefly, Sm16 ORF was amplified from S. mansoni cercarial cDNA with gene-specific primers as described earlier. 8 The forward primer (5'-CCGGAATTCATGAAAGTGACGCCAATTA TC-3') encoded the first 21 bp of ORF flanked with EcoRI restriction site and the reverse primer (5'-CGCGGATCCAGACGATTCATATTCCATC) contained the last 19 bp of ORF flanked by BamHI site. The stop codon was removed from Sm16 gene, so that the gene could be inserted preserving the reading frame of EGFP gene. This will facilitate the expression of Sm16 protein as N-terminus fusion to EGFP. The resultant recombinant was termed Sm16:GFP. DNA insert in the recombinant was sequenced on both the strands to ensure authenticity of the cloned gene. Intradermal delivery of plasmid DNA Recombinant plasmids were purified using a Qiagen Maxi plasmid extraction kit (Qiagen, Valencia, CA, USA) as per the manufacturer's recommendations. About 25 g of plasmid DNA suspended in 50 l of sterile PBS was injected intradermally into the dorsal skin of the ears or into the shaved abdominal skin of 4-week-old C57BL/6 mice using a 1-ml syringe and 28-gauge needle. Empty cloning vectors were used as controls. Mice were purchased from Charles River Laboratories (Wilmington, MA, USA) and were treated in accordance with an approved institutional protocol.
Recovery of migratory cells from ear explants
Twenty-four hours after the injection of DNA or vector control into the dorsal skin of the ears, skin was removed and migratory cells were collected as described previously. 31 Briefly, mouse ears were excised and skin was peeled under microscope into two halves. The ear halves were washed once in RPMI-1640 media and floated dermal side down in complete medium (RPMI-1640 with 10% FBS and 50 g/ml gentamicin) and incubated for 72 h. Following incubation the skin pieces were removed and non-adherent cells that has migrated into the media were collected for RT-PCR analysis.
Flow cytometry
Cells emigrating out of the skin explants were collected and stained with rat anti-mouse DEC-205 antibodies (Peninsula Laboratories, San Carlos, CA, USA) for 1 h over ice. After washing three times in RPMI medium, cells were stained with PE-labeled anti rat IgG2a (Pharmingen, San Diego, CA, USA) for 1 h over ice and counted in a flow cytometer (Cytron, Ortho Diagnostics Gene Therapy Systems, Raritan, NJ, USA). Rat IgG2a (Pharmingen) was used as the negative controls.
RT-PCR
Total RNA was extracted from the cells or from whole skin using a TRIZOL reagent (Life Technologies) and reverse transcribed using RNaseH -superscript RT (Life Technologies). PCR amplification was performed with gene-specific primers for Sm16 (Ref. 8; synthesized at IDT Inc, Coralville, IA, USA), IL-1␤ (Ambion, Hoston, TX, USA) and TNF-␣ (Ambion). PCR conditions were as recommended by the manufacturer. Transcripts of glyceraldehyde-3-phosphate-dehydrogenase (G3PDH) gene served as internal control. RNA samples without the addition of RT served as a control for identifying possible contamination with genomic or plasmid DNA. PCR products were separated in an agarose gel and stained with ethidium bromide. The image of the electrophoretic profile was then scanned and the intensity of bands was quantified using an NIH Image software. Values are normalized to the intensity of G3PDH transcripts from the respective samples and results are expressed as fold increase/decrease of gene expression over controls.
Macro gene array for evaluating cytokine mRNA expression
Custom macro gene array for profiling mouse IL-1␣, IL-1␤, IL-17, MIP-1␣, MIP-2␣, TGF-␤ and TNF-␣ were purchased from Superarray (Bethesda, MD, USA). One of the greatest advantages of this analysis is its versatility to analyze multiple cytokine genes in a single assay. ␤-Actin and G3PDH were used as positive controls and pUC-18 DNA was used as negative control. Briefly, 5 g of total RNA prepared as described above were converted to biotin-labeled cDNA and hybridized overnight with gene array membrane. Following hybridization, the membrane was rinsed in buffer and incubated further with alkaline phosphatase-labeled streptavidin. Signal was developed using a CDP-star substrate and image captured on X-ray film. Each spot was scanned using an NIH image software and intensity of the hybridization signal was quantified. After subtracting the background, the signal values for each sample were normalized to the intensity of G3PDH transcripts. The results are expressed as fold increase/decrease of gene expression over controls.
Fluorescence microscopy
Skin samples were collected at 24 h, 48 h, 72 h and on days 7, 12 and 20 after intradermal delivery of Sm16:GFP construct and were snap frozen in OCT compound (Sakura Finetek, Torrance, CA, USA). About 8-m sections were cut using a cryostat. Section were fixed in 4% formalin and mounted in aqueous mount (Biomeds, Foster City, CA, USA) before observation under a fluorescent microscope.
DNA and LPS injection schedule
Twenty-five micrograms of CMV:Sm16 DNA or control plasmid DNA was injected intradermally into the shaved abdominal skin of mice at Ϫ48 h, Ϫ24 h, 0 h, 24 h, or 48 h after an injection of 5 g of LPS (Sigma) into the same skin site. Skin samples from the site of injection were collected 72 h after LPS (for Ϫ48, Ϫ24 and 0 h time-points) or Sm16 DNA injection (for 24 and 48 h time-point) and analyzed for neutrophil infiltration and ICAM-1 expression.
Histology and immunohistochemistry
Skin samples collected from the site of injection were cut into two halves. The first half was processed for histology and the second half for immunohistochemistry. For histology, 5-m sections were cut from the paraffin block and stained with hematoxylin-eosin to determine the neutrophil infiltration. For immunohistochemistry, 8-m sections prepared using a cryostat were immunostained with biotinylated monoclonal antibody against mouse CD54 (Pharmingen). Alkaline phosphatase-labeled streptavidin (Pierce Chemicals, Rockford, IL, USA) was used as the secondary antibody and color was developed using fast red substrate (Pierce Chemicals).
Proliferation assays
Inguinal lymph nodes were collected at 24 h, 48 h, 72 h and on day 7 after injecting plasmid DNA into the abdominal skin of mice. Single cell suspensions were prepared and 1 × 10 6 cells/ml were stimulated with 5 g/ml of ConA (Sigma) for 72 h to induce proliferation. Cells prepared similarly from vector alone-injected animals served as controls. Cell proliferation was quantitated using a CellTiter 96 AQ non-radioactive cell proliferation assay kit (Promega, Madison, WI, USA).
Serological studies
Mice were injected intradermally into the abdominal skin with 25 g of either CMV vector control or CMV: Sm16 construct three times at 2-week intervals. Blood samples were collected from retro-orbital space on 0, 2, 4, 6 and 8 weeks after the initial DNA injection, sera separated and assayed for antibody response by ELISA and Western blotting. For ELISA, 96-well plates were coated overnight with 50 ng/ml of Sm16 protein suspended in 0.1 m carbonate buffer (pH 9.0). After blocking with 5% BSA for 1 h, 1:50 dilution of the mouse sera was added and incubated at room temperature for 3 h. Wells were washed six times with PBS-tween and incubated with 1:5000 dilution of an HRP-labeled rabbit anti-mouse antibody (Pierce Chemicals). The color was developed using an OPD substrate. For Western blotting, ES products of S. mansoni containing Sm16 was separated on SDS-PAGE and blotted on to nitrocellulose membrane. After blocking with 5% skim milk powder, blots were incubated with 1:50 dilution of mouse sera and probed with HRP labeled rabbit anti-mouse antibody (Pierce Chemicals). Positive signal was visualized using an ECL (Enhanced Chemoluminescence) detection system (Amersham, Piscataway, NJ, USA).
